Summary: A new clinical trial reports that deep brain stimulation (DBS) produced meaningful symptom improvement in half of adults with treatment-resistant depression, and nearly one-third achieved remission. The study identified theta-frequency (4–8 Hz) electrical activity in the bed nucleus of the stria terminalis (BNST) as a predictive biomarker of individual treatment response.
Patients with lower BNST theta activity before surgery and stronger theta-band coherence between the BNST and prefrontal cortex showed the greatest clinical benefit. The findings point toward personalised DBS strategies and support the feasibility of adaptive, closed-loop stimulation guided by real-time brain signals.
Key Facts:
- Predictive biomarker: Lower BNST theta power prior to implantation predicted larger reductions in depression and anxiety.
- Response rate: 13 of 26 patients (50%) demonstrated significant clinical improvement; 9 patients (35%) reached remission of core symptoms.
- Closed-loop potential: DBS reduced BNST theta activity in parallel with symptom relief, supporting future adaptive stimulation systems that respond to ongoing brain activity.
Source: University of Cambridge
Deep brain stimulation — electrically active implants that function like a pacemaker for the brain — produced clear clinical benefits for many participants with severe, treatment-resistant depression in an open-label trial.
The multicentre study, led by teams in the UK and China, not only demonstrated symptomatic improvement but also discovered a measurable brain signature that predicts which patients are most likely to respond. That objective signal could help clinicians select candidates for DBS and tailor stimulation settings.
Major depressive disorder is a leading cause of disability worldwide. While pharmacological and psychological treatments help many people, a substantial proportion of patients remain refractory to standard care. New, effective options are urgently needed for those with treatment-resistant depression.
DBS has been used for several neurological and psychiatric conditions, most notably Parkinson’s disease. The method places fine electrodes deep in specific brain regions to deliver continuous or patterned electrical pulses intended to normalise dysfunctional circuitry.
This trial, reported in Nature Communications, enrolled 26 adults with treatment-resistant depression from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The study was open-label, meaning participants and researchers were aware that DBS was being delivered during the response assessment period.
Stimulation targeted two interconnected regions: the bed nucleus of the stria terminalis (BNST), a limbic structure implicated in prolonged anxiety, stress and social threat responses; and the nucleus accumbens (NAc), a core hub for reward processing, motivation and reinforcement learning.
Clinically, half of the cohort (13/26) experienced substantial improvements on standardized measures of depression and anxiety, along with gains in quality of life and reduced disability. Nine participants (35%) met criteria for remission, defined as near-complete resolution of core depressive symptoms.
The research team recorded intracranial field potentials from the BNST electrodes alongside scalp EEG. They identified theta-band activity (4–8 Hz) in the BNST as clinically relevant: higher BNST theta power correlated with worse day-to-day mood and anxiety, while lower preoperative theta predicted greater symptom improvement after DBS.
In addition, stronger theta coherence between the BNST and prefrontal cortex — indicating tighter synchrony and communication in this frequency band — was associated with better treatment outcomes. The prefrontal cortex is central to emotional regulation, and greater BNST–prefrontal coupling appears to mark a network state that responds well to stimulation.
During chronic stimulation, reductions in BNST theta tracked symptomatic relief, a relationship that supports development of closed-loop systems. In such an adaptive approach, the stimulator could increase stimulation when theta rises (signalling worsening anxiety) and reduce stimulation when theta falls, improving efficacy and potentially limiting side effects.
The investigators also identified simple behavioural predictors: participants who showed especially strong negative emotional reactions to aversive images were less likely to benefit from DBS, suggesting that neuropsychological profiling could complement physiological biomarkers in candidate selection.
Funding for the study came from the National Natural Science Foundation of China and the Science and Technology Commission of Shanghai Municipality, with additional support for parts of the team from the UK Medical Research Council.
Alongside the open-label phase, the group completed a double-blind, randomised controlled trial of BNST–NAc DBS; those results are expected to be published separately and will provide a rigorous test of efficacy without awareness-related biases.
Key Questions Answered:
A: Lower theta-frequency (4–8 Hz) activity in the BNST measured before treatment strongly predicts a better clinical response.
A: In the open-label phase, 50% of participants improved significantly and 35% reached remission of core symptoms.
A: It enables more personalised DBS approaches and supports the development of real-time, closed-loop stimulation systems that adapt to a patient’s brain state.
Editors Notes
- This piece was prepared by a Neuroscience News editor.
- The full journal paper was reviewed for this summary.
- Additional contextual details were provided by editorial staff.
About this neurotech and depression research news
Author: Craig Brierley
Source: University of Cambridge
Contact: Craig Brierley – University of Cambridge
Image: Image credit: Neuroscience News
Original Research: Open access. “Prefrontal–Bed Nucleus of the Stria Terminalis Physiological and Neuropsychological Biomarkers Predict Therapeutic Outcomes in Depression” by Valerie Voon et al., published in Nature Communications.
Abstract
Prefrontal–Bed Nucleus of the Stria Terminalis Physiological and Neuropsychological Biomarkers Predict Therapeutic Outcomes in Depression
Effective treatments for refractory depression are urgently needed. This study evaluated deep brain stimulation (DBS) targeting the bed nucleus of the stria terminalis (BNST) and nucleus accumbens (NAc) in 26 patients with treatment-resistant depression to measure therapeutic benefit and identify predictors of response.
In the open-label phase, BNST–NAc DBS produced a 50% response rate and a 35% remission rate. Using acute and chronic intracranial recordings, scalp EEG, machine learning, neuroimaging and behavioural assessment, the team identified objective biomarkers: lower BNST theta power and greater prefrontal–BNST theta coherence, together with top‑down connectivity, predicted better depression outcomes and improved quality of life at 3, 6 and 12 months. These findings were robust across eyes-open and eyes-closed conditions and confirmed with machine-learning analyses.
The study mapped a physiology-guided connectivity network involving dorsal anterior cingulate and lateral inferior frontal cortex tracts. The biomarkers were linked to negative emotional bias and anxiety, highlighting both the efficacy of BNST–NAc DBS for refractory depression and broader clinical implications. ClinicalTrials.gov registration: NCT04530942.